John Leonard - Iqvia Holdings Independent Director

<div class='circular--portrait' style='background:#0D52D1;color: white;font-size:5em;padding-top: 5px;;'>Q</div>
  Director
Dr. John M. Leonard, M.D. is Independent Director of Company. Since July 2014, Dr. Leonard serves as Executive Vice President, RD, at Intellia Therapeutics, Inc., a biotechnology company involved in genebased therapy. Dr. Leonard previously served as the Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie Inc., a global pharmaceutical company, from its spinout from Abbott Laboratories in January 2013 until retiring from those positions at the end of 2013. Prior to the formation of AbbVie, Dr. Leonard served as Senior Vice President of Global Pharmaceutical Research and Development at Abbott from 2008 to 2012. He has over 30 years of combined experience in medicine, research and management, including serving in various roles at Abbott beginning in 1992. Dr. Leonard also serves as a director of Chimerix, Inc. and Intellia Therapeutics, Inc. Dr. Leonard earned a Bachelors Degree in Biochemistry from the University of Wisconsin at Madison and a Doctorate in Medicine from Johns Hopkins University in Baltimore, MD. Dr. Leonard completed an Internship and Residency in Internal Medicine at Stanford University Hospital followed by a Postdoctoral Fellowship in Molecular Virology at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. Dr. Leonard serves as a member of the Audit Committee and as a member of the Nominating and Governance Committee.
Age: 58  Director Since 2015  Ph.D    
919-998-2000  www.quintiles.com
Leonard earned a Bachelor?s Degree in Biochemistry from the University of Wisconsin at Madison and a Doctorate in Medicine from Johns Hopkins University in Baltimore, MD.

John Leonard Latest Insider Activity

Management Efficiency

The company has return on total asset of 4.03 % which means that for every 100 dollars spent on asset it generated profit of $4.03. This is acceptable considering the industry classification. Similarly, it shows return on equity (ROE) of 1.89 % implying that it made 1.89 on every $100 invested by shareholders.
The company has accumulated 9.77 B in total debt with debt to equity ratio (D/E) of 130.0 implying that the company may be unable to produce cash to meet its debt commitments. Iqvia Holdings has Current Ratio of 1.2 implying that it may have difficulties to pay its interest payments when they become due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Joachim FaberHSBC HOLDINGS PLC
2012
MayLung ChaHSBC HOLDINGS PLC
2011
Marc DesmidtIshares FtseXinhua A50
2012
Graham TurlIshares FtseXinhua A50
2014
Julie BrownRoche Holdings Ag Beare
2016
Beatrice MauroRoche Holdings Ag Beare
2006
Janis LomaxHSBC HOLDINGS PLC
2015
Michael MarquardtIshares FtseXinhua A50
2009
Pius BascheraRoche Holdings Ag Beare
2007
Mark McCombeIshares FtseXinhua A50
2012
Phillip AmeenHSBC HOLDINGS PLC
2015
John LipskyHSBC HOLDINGS PLC
2012
Jane LeungIshares FtseXinhua A50
2012
Philip AmeenHSBC HOLDINGS PLC
2015
Peter VoserRoche Holdings Ag Beare
2011
David NishHSBC HOLDINGS PLC
2016
Kathleen CaseyHSBC HOLDINGS PLC
2014
Paul BulckeRoche Holdings Ag Beare
2011
Anita HauserRoche Holdings Ag Beare
2017
Paul WalshHSBC HOLDINGS PLC
2016
Bernard PoussotRoche Holdings Ag Beare
2015

Entity Summary

Quintiles IMS Holdings, Inc. offer biopharmaceutical development services and commercial outsourcing services in the Americas, Europe, Africa, and the AsiaPacific. Iqvia Holdings (Q) is traded on BATS Exchange in USA and employs 36,100 people.

Iqvia Holdings Leadership Team

Thomas Pike, CEO and Director
Ari Bousbib, Director
Michael Evanisko, Independent Director
Leonard Schaeffer, Independent Director
James Erlinger, Executive Vice President General Counsel, Secretary
John Danhakl, Director
Richard Staub, President - Research and Development Solutions
Michael McDonnell, CFO, Executive Vice President
Kevin Gordon, COO
John Leonard, Independent Director
James Fasano, Director
Jonathan Coslet, Director
John Connaughton, Director
Haiyuan Lo, Director
Ronald Rittenmeyer, Director
Dennis Gillings, Executive Chairman of the Board
Todd Sisitsky, Director
Jack Greenberg, Independent Director
Kevin Knightly, President - Information and Technology Solutions

Stock Performance Indicators

Current Sentiment - Q

Iqvia Holdings Investor Sentiment

More than half of Macroaxis users are at this time bullish on Iqvia Holdings. What is your judgment towards investing in Iqvia Holdings? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

ALNY   
Purchased few shares of
few hours ago
Traded for 1.0
TWTR   
Purchased over 50 shares of
few hours ago
Traded for 1.0
BTCS   
Purchased over 100 shares of
few hours ago
Traded for 1.0
BTSC   
Purchased over 10K shares of
few hours ago
Traded for 1.0
SQ   
Purchased few shares of
few hours ago
Traded for 1.0
See also Your Equity Center. Please also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..